US FDA drug registration

I. Registration Types and Core Processes

1. New Drug Application (NDA): Applicable to new chemical entities or biologics, requiring submission of complete non-clinical and clinical data (Phases I-III). The standard review cycle is typically 10 months, shortened to 6 months under priority review. In 2025, the new Commissioner's National Priority Voucher (CNPV) program was introduced, allowing drugs aligned with national health priorities to complete review within 1-2 months through concentrated interdisciplinary team evaluation and the ELSA AI tool to enhance efficiency.

2. Abbreviated New Drug Application (ANDA): Demonstrates equivalence to the reference listed drug through bioequivalence (BE) studies without repeating clinical research. The 2025 generic drug user fee is $540,783 standard / $135,196 for small businesses.

3. Biologics License Application (BLA): For biologic products (e.g., monoclonal antibodies, vaccines), requiring submission of manufacturing process, quality control, and clinical data. Biosimilars follow the streamlined 351(k) pathway for review.

4. Over-the-Counter (OTC) Drugs: Divided into the monograph process and the NDA process. Under 2025 new rules, minor dosage form changes such as converting tablets/capsules to chewable tablets or orally disintegrating tablets no longer require additional approval, provided dissolution profile equivalence is demonstrated; meanwhile, orally disintegrating tablets and film formulations are required to adopt unit-dose packaging to enhance safety. OTC products conforming to a monograph must complete NDC registration (National Drug Code), with a process of approximately 45 days.

5. Drug Master File (DMF): Categorized into Type II (active pharmaceutical ingredient), Type III (packaging materials), etc., and must be linked to a drug product application through cross-referenced review. The 2025 stability testing guidance (ICH Q1 consolidated version) requires more detailed data for complex biologics.

II. Key Time and Fee Data (2025)

• Review Timelines:

• Standard NDA/BLA: 10 months (standard) / 6 months (priority)

• CNPV Program: 1-2 months (requires advance submission of CMC and draft labeling)

• ANDA: Approximately 10 months (including GMP inspection)

• Fees:

• NDA Application Fee: $4,310,002 (with clinical data), $2,155,001 (without clinical data)

• Prescription Drug Program Fee: $403,889 (regardless of application type)

• Generic Drug / Biosimilar Annual Fee: $162,235 (standard) / $40,559 (small business)

• International Service Fees: When using an agent, registration service fees range from approximately $395-$495 (food/cosmetics) to $63,291 (medical devices).

III. Accelerated Approval Pathways and Innovative Mechanisms

1. Breakthrough Therapy Designation: Applicable to drugs for serious conditions where preliminary clinical data demonstrate substantial improvement over existing therapies, allowing early FDA engagement and rolling review.

2. Priority Review Voucher (PRV): Companies developing drugs for rare pediatric diseases may obtain priority review eligibility. The 2025 BIO Convention called for reauthorization of the Rare Pediatric Disease Priority Review Voucher Program to incentivize R&D.

3. Real-Time Oncology Review (RTOR): For oncology drugs, allows phased data submission to shorten time to market.

4. Digital Health Integration: In 2025, the FDA further advanced electronic submissions (eCTD) and automated clinical data analysis through the ELSA tool to reduce human error.

IV. Key Requirements for International Applicants

1. GMP Inspection: Manufacturing facilities must pass an FDA on-site inspection. For example, Bloomage Biotechnology passed the cGMP inspection for sodium hyaluronate API with zero defects in 2025. Inspection focus areas include quality systems, production records, and change control.

2. Data Mutual Recognition: Since China joined ICH in 2017, clinical trial data may be accepted by the FDA, provided it complies with standards such as ICH E6(R2). Traditional Chinese medicines must follow the botanical drug pathway for NDA submission, requiring demonstration of compositional consistency and clinical efficacy.

3. U.S. Agent: Non-U.S. companies must designate a U.S. Agent to handle communications and document submissions, with fees of approximately $1,000-$5,000 per year.

V. Key Considerations

1. Patents and Exclusivity: ANDA submissions require a Paragraph IV certification challenging the innovator's patent; upon success, 180-day market exclusivity may be granted. NDA drugs are entitled to 5 years of data exclusivity, extended to 7 years for orphan drugs.

2. Post-Market Surveillance: Periodic safety update reports (PSUR) must be submitted regularly, and Phase IV clinical trials may be conducted. The 2025 stability guidance requires continuous quality monitoring throughout the product lifecycle.

3. OTC Monograph Updates: Companies may submit an OTC Monograph Order Request (OMOR) to drive ingredient or indication expansions, such as the 2025 sunscreen monograph adding broad-spectrum protection requirements.

VI. Resources and Tools

• Official Guidance: The FDA website provides documents including the Drug Registration Applicant Guidance and eCTD Technical Specifications. The 2025 Q1 stability testing guidance consolidates the ICH Q1 series standards.

• Technical Support: The FDA has established an International Programs Office to provide consultation for non-U.S. companies. Small and medium-sized enterprises may apply for fee reductions (e.g., ANDA small business rate at 25% of standard).

• Industry Collaboration: Participating in international conferences such as the BIO Convention provides access to the latest developments; for example, the 2025 conference focused on AI applications in drug development and global supply chain optimization.

Summary